ORIC Pharmaceuticalsの空売り状況は、投資家がORIC Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

ORIC Pharmaceuticals (NASDAQ:ORIC) 株価情報, 空売り情報

ORIC PHARMACEUTICALS INC

ORIC Pharmaceuticals

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals Inc

Orica Ltd

<a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">Robinhood Markets, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) has signed an agreement to acquire WonderFi Technologies Inc., a Canadian cryptocurrency platform, in an all-cash transaction valued at approximately $178 million.
What Happened: The purchase price of $0.26 per share represents a 41 percent premium over WonderFi's closing price on May 12 and a 71 percent premium over its 30-day volume-weighted average price, according to a company <a href="https://newsroom.aboutrobinhood.com/robinhood-to-acquire-wonderfi/">statement</a>.
WonderFi operates Bitbuy and Coinsquare, two regulated cryptocurrency exchanges in Canada, with a reported $1.49 billion in assets under custody. 
The company will continue operating its platforms after the transaction closes. 
The deal is expected to be completed in the second half of 2025, subject to shareholder approval, regulatory review and court authorization.
Robinhood, which opened a Canadian headquarters in Toronto in 2024, will incorporate WonderFi's operations into its existing crypto business. 
According to the agreement, WonderFi's leadership team is expected to remain with the company following the acquisition. 
Employees will be added to Robinhood's Canadian workforce, which currently includes over 140 people.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45371362/coinbase-could-see-up-to-16b-net-inflows-after-sp-500-entry-bernstein">Coinbase Could See Up To $16B Net Inflows After S&amp;P 500 Entry: Bernstein</a>
The acquisition will be carried out under a statutory plan of arrangement governed by British Columbia corporate law. 
Robinhood plans to fund the purchase using existing cash reserves. No stock issuance or debt financing will be used to support the transaction.
WonderFi shareholders will receive the full purchase amount in cash. 
The company's common shares are currently listed on the Toronto Stock Exchange. The combined equity value of the transaction, on a fully diluted basis, stands at approximately $178 million.
Advisors on the deal include J.P. Morgan Securities for Robinhood and Financial Technology Partners for WonderFi. 
Legal counsel was provided by Canadian firms on both sides, including Goodmans LLP, Cassels Brock &amp; Blackwell LLP, and Mintz LLP.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45356864/cardano-up-23-in-7-days-as-co-founder-charles-hoskinson-explores-privacy-focused-stablecoin">Cardano Up 23% In 7 Days As Co-Founder Charles Hoskinson Explores Privacy-Focused Stablecoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

HOOD

Robinhood To Acquire Canada's WonderFi For $178M All-Cash Deal

Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) on Tuesday reported a third quarter 2025 loss of 44 cents per share, down from a <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">loss of $1.43 a year ago</a>.
The noninvasive testing solutions provider reported sales of $728.87 thousand, down from $823.80 thousand a year ago.
Total revenues increased 20% quarter-over-quarter, supported by ongoing expansion across safety-critical industries and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">steady customer acquisition</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44472191/exclusive-fda-seeks-additional-information-for-intelligent-bio-solutions-drug-screening-system-clearance-process-remains-on-track-for-2025-us-launch" rel="noreferrer noopener">EXCLUSIVE: FDA Seeks Additional Information For Intelligent Bio Solutions' Drug Screening System, Clearance Process Remains on Track For 2025 US Launch</a>
As we expand further into new markets, our focus on growing cartridge adoption, our highest-margin revenue stream, is strengthening the business fundamentals," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions.
"We've also seen a notable reduction in losses this quarter, reflecting ongoing improvements in cost control and operational efficiency. To support global scalability, we introduced multilingual functionality across our drug screening system and websites, ensuring our solution is widely accessible, commercially viable, and ready for broader distribution across international markets. We believe these efforts are laying a strong foundation for long-term, sustainable revenue growth."
The company secured 35 new accounts during the quarter ended March 31, 2025, bringing its total active account base to over 450.
Cartridge revenue increased from 49% to 58% for the nine months ended March 31, 2025, an increase of 9 percentage points compared to the same period in 2024.
As of March 31, 2025, total cash and cash equivalents were $2.81 million.&nbsp;
Gross profits for the fiscal third quarter were $341,368, an increase of 91% year-over-year.
Increases in gross profit are mainly attributable to enhanced production capacity, which has reduced direct labor, direct materials, and direct product-related overhead costs.
The company said it continues to improve its strategic sales mix and operational streamlining, thus driving increased gross profit.&nbsp;
Net loss attributable to the company decreased to $2.54 million from $2.98 million a year ago.
During the fiscal third quarter, the company advanced its international growth strategy and product readiness through a series of targeted initiatives. These included expanded access in key European markets, multilingual upgrades to its drug screening system and digital outlets, and further protection of its core intellectual property portfolio. Intelligent Bio said these developments support its ability to scale globally and drive sustained commercial growth.
In March, Intelligent Bio received a U.S. patent for its Intelligent <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44491787/exclusive-intelligent-bio-solutions-adds-sixth-us-patent-for-its-drug-screening-technology" rel="noreferrer noopener">Fingerprinting Drug Screening Cartridge</a>.&nbsp;
This&nbsp;is the company's sixth active patent to be granted in the U.S., strengthening the protection of its unique and proprietary drug screening technology.&nbsp;
U.S. Patent (12259385)&nbsp;relates to the proprietary lateral flow test strip inside the company's Drug Screening Cartridge.
Price Action: At the last check on Tuesday, INBS stock was up 4.92% at $1.28 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45371916/exclusive-alzamend-neuro-initiates-first-phase-2-trial-of-lead-program-in-healthy-human-participants" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants</a></li>
</ul>

Earnings

Health Care

Market-Moving Exclusives

Exclusives

Movers

General

Intelligent Bio Solutions Inc. - Common Stock

INBS

EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Compass Point analyst Merrill Ross downgraded the rating for Independence Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Buy to Neutral and announced a $22 price target. Independence Realty Trust shares closed at $19.31 on Monday. <a href="https://www.benzinga.com/quote/IRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Rudy Kessinger downgraded the rating for Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Neutral to Underperform and lowered the price target from $29 to $21. Rapid7 shares closed at $26.74 on Monday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point analyst Merrill Ross downgraded NexPoint Residential Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) from Buy to Neutral and slashed the price target from $50 to $42.5. NexPoint Residential shares closed at $37.53 on Monday. <a href="https://www.benzinga.com/quote/NXRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Daina Graybosch downgraded Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Outperform to Market Perform and cut the price target from $5 to $0.39. Affimed shares closed at $0.6930 on Monday. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying RPD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-1024x576.png" alt="" class="wp-image-913351" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AFMD

NXRT

This Rapid7 Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday

Throughout the last three months, 4 analysts have evaluated Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $7.25, with a high estimate of $8.00 and a low estimate of $6.00. A decline of 12.12% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747137639_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Indie Semiconductor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Indie Semiconductor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Indie Semiconductor compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Indie Semiconductor's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Indie Semiconductor's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INDI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Indie Semiconductor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Indie Semiconductor: A Closer Look</h2>
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for advanced Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the advanced user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.
<h3>Financial Milestones: Indie Semiconductor's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Indie Semiconductor faced challenges, resulting in a decline of approximately -17.29% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -56.17%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -7.43%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.75%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.95, Indie Semiconductor adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INDI

Beyond The Numbers: 4 Analysts Discuss Indie Semiconductor Stock

Throughout the last three months, 4 analysts have evaluated NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated NexPoint Residential and provided 12-month price targets. The average target is $42.88, accompanied by a high estimate of $44.00 and a low estimate of $42.00. Highlighting a 5.76% decrease, the current average has fallen from the previous average price target of $45.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747137626_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of NexPoint Residential's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.50</td>
<td>$50.00</td>
</tr>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Linda Tsai</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$43.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$42.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NexPoint Residential. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NexPoint Residential compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for NexPoint Residential's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of NexPoint Residential's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NXRT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NexPoint Residential analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About NexPoint Residential</h2>
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
<h3>NexPoint Residential: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, NexPoint Residential faced challenges, resulting in a decline of approximately -6.45% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: NexPoint Residential's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -10.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.75%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): NexPoint Residential's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.36%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.86, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss NexPoint Residential Stock

EXCLUSIVE: Intelligent Bio Solutions Tells Benzinga 'Gross profits for the fiscal third quarter were $341,368, an increase of 91% year-over-year'

EXCLUSIVE: Intelligent Bio Solutions Tells Benzinga 'Total revenues for the fiscal third quarter were $0.73 million, an increase of 20% quarter-over-quarter'

WIIM

NMRA

Neumora Therapeutics shares are trading higher. The company reported Q1 financial results.

EXCLUSIVE: Intelligent Bio Solutions Tells Benzinga Co. Reports Q3 2025 Financial Results, Says '20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth'

Needham analyst Mike Matson reiterates LivaNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>) with a Buy and maintains $64 price target.

Price Target

Reiteration

LIVN

Needham Reiterates Buy on LivaNova, Maintains $64 Price Target

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy and maintains $36 price target.

OMER

D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

Biotech

ITOS

iTeos Has Initiated A Targeted Review Of Strategic Alternatives To Maximize Shareholder Value

–&nbsp;GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival
–&nbsp;Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program
–&nbsp;iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value
WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported topline results from an updated interim analysis of GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos' development partner GSK assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer (NSCLC).
The GALAXIES Lung-201 data continued to demonstrate clinically meaningful improvements in the trial's primary endpoint of objective response rate (ORR), however the analysis did not meet established criteria for clinically meaningful improvements in the secondary endpoint of progression free survival in the belrestotug + dostarlimab combination cohorts versus dostarlimab monotherapy. Additionally, an interim analysis of the GALAXIES H&amp;N-202 Phase 2 trial showed a trend below the meaningful threshold for ORR in the belrestotug combination cohorts vs. dostarlimab monotherapy in PD-L1 positive head and neck squamous cell carcinoma.
Based on these results, iTeos and GSK have made the decision to terminate the belrestotug development program and end the collaboration. All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial is ending. GSK is communicating with investigators, institutional review boards, ethics committees, and health authorities about next steps for appropriate management of currently enrolled patients. The Company is taking immediate steps to preserve capital and has initiated a targeted process to identify opportunities that preserve and maximize shareholder value. iTeos has engaged TD Cowen to advise on this process.&nbsp;

iTeos Reports Topline Interim Results From GALAXIES Lung-201 Study Of Belrestotug + Dostarlimab In First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients; Did Not Meet Established Criteria For Clinically Meaningful Improvements In Progression Free Survival; Based On Totality Of Data, ITeos And GSK Have Agreed To Terminate The Belrestotug Development Program

MVIS

MicroVision shares are trading lower after the company reported worse-than-expected Q1 financial results.

NRGV

NRGV stock has given up its prior loss. Energy Vault Holdings shares were trading lower after the company reported worse-than-expected Q1 financial results.

Anthony Scaramucci believes Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is in the midst of a structural transformation, from a volatile tech-aligned investment to a maturing global asset more comparable <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44932297/digital-gold-or-fools-gold-the-real-value-behind-bitcoin-in-2025#:~:text=In%20truth%2C%20Bitcoin%20isn't,stored%20with%20zero%20physical%20footprint.">to digital gold</a>.
What Happened: In an <a href="https://x.com/Cointelegraph/status/1922185336572010570">interview</a> with Bloomberg on Monday, the SkyBridge Capital founder said Bitcoin's growing adoption and long-term holding behavior are driving this evolution, dampening volatility and pushing it into the asset class category rather than a speculative investment.
"Ultimately, what we see is the evolution of Bitcoin from being sort of a tech asset tied to the Mag 7 or Nasdaq to something that's more akin to digital gold," Scaramucci said. 
As wallet growth accelerates, now estimated at over 300 million globally, he anticipates that broader adoption could lead to a billion holders, a milestone that would reduce price swings and reinforce Bitcoin's role in long-term portfolios.
He added that this cycle of increasing wallet distribution, institutional participation and reduced volatility could form a positive feedback loop, encouraging more large holders to enter the market.
The shift, he argued, prompts a key distinction: "Is Bitcoin an investment, or is it an asset class?" 
If the latter, he said, then valuations would shift from a market cap in the trillions, similar to tech stocks, to the levels of gold, which commands over $22 trillion in global value.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45352237/nakamoto-holdings-raises-710m-merges-with-kindlymd-to-build-bitcoin-treasury-holding-company">Nakamoto Holdings Raises $710M, Merges With KindlyMD To Build Bitcoin Treasury Holding Company</a>
Why It Matters: The remarks come as Bitcoin continues to consolidate above the $103,000 mark.
Bitfinex analysts report steady spot volume and neutral funding, with no immediate macro threats. 
Support lies near $98,500, while resistance stands between $104,000 and $106,000. 
In a note sent to Benzinga, the analysts caution that while momentum remains intact, Bitcoin may enter a consolidation phase, potentially delaying any new all-time highs until June as supply and demand stabilize above key psychological thresholds.
Medium-term conditions remain constructive. 
Bitcoin has outperformed equities and altcoins, and ETF inflows continue to show consistency. 
Barring any shocks from CPI data or central bank guidance, analysts see further upside in the months ahead.
Long-term, Bitfinex analysts echo Scaramucci's perspective, stating that Bitcoin is increasingly behaving like a macro reserve asset. 
Structural supply limitations, global ETF adoption, and a shift in U.S. regulatory tone have strengthened Bitcoin's fundamental outlook. 
Price targets between $150,000 and $180,000 for the current cycle remain in play, contingent on broader market stability.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45349057/strategy-buys-134b-in-bitcoin-at-99856-cites-155-btc-yield">Strategy Buys $1.34B In Bitcoin At $99,856, Cites 15.5% BTC Yield</a></li>
</ul>
Image: Shutterstock

$BTC

Anthony Scaramucci Says Bitcoin Is Evolving From A Tech Asset To Digital Gold

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Holdings shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Needham analyst Joshua Reilly reiterates Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) with a Buy and maintains $750 price target.

Needham Reiterates Buy on Tyler Technologies, Maintains $750 Price Target

RLGT

Radiant Logistics shares are trading higher after the company reported better-than-expected Q3 financial results.

SNGX

Soligenix shares are trading lower after the company reported worse-than-expected Q1 EPS results.

Press Releases

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Comments

ORIC Pharmaceuticals

空売り

ORIC Pharmaceuticals (NASDAQ:ORIC) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル